Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/abbvie-inc-c0b93f23-6aae-45aa-858d-04ac387d1825">AbbVie </a>is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, driven by the robust growth of its next-generation immunology therapies, Skyrizi and Rinvoq, which are on track to collectively exceed Humira's peak sales.</li>
  <li>The company has built a diversified portfolio through strategic acquisitions, notably Allergan, which added leading aesthetics (Botox) and neuroscience franchises, reducing its reliance on immunology and providing new avenues for growth.</li>
  <li>
<a href="https://smartkarma.com/entities/abbvie-inc-c0b93f23-6aae-45aa-858d-04ac387d1825">AbbVie </a>remains a compelling investment for income-oriented investors, demonstrating a strong commitment to shareholder returns through a consistently growing dividend, supported by strong free cash flow generation. The company is a member of the S&amp;P Dividend Aristocrats Index.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
AbbVie is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, driven by the robust growth of its next-generation immunology therapies, Skyrizi and Rinvoq, which are on track to collectively exceed Humira's peak sales.
  The company has built a diversified portfolio through strategic acquisitions, notably Allergan, which added leading aesthetics (Botox) and neuroscience franchises, reducing its reliance on immunology and providing new avenues for growth.
  
AbbVie remains a compelling investment for income-oriented investors, demonstrating a strong commitment to shareholder returns through a consistently growing dividend, supported by strong free cash flow generation. The company is a member of the S&amp;P Dividend Aristocrats Index.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson's, and alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AbbVie (ABBV UN)

Primer: AbbVie (ABBV UN) - Sep 2025

AbbVie is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, driven by the robust growth of its...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)